2021
DOI: 10.1186/s12872-021-02348-0
|View full text |Cite
|
Sign up to set email alerts
|

The CADILLAC risk score accurately identifies patients at low risk for in-hospital mortality and adverse cardiovascular events following ST elevation myocardial infarction

Abstract: Background The CADILLAC risk score was developed to identify patients at low risk for adverse cardiovascular events following ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PPCI). Methods We performed a single center retrospective review of STEMI hospitalizations treated with PPCI from 2014 to 2018. Patients were stratified using the CADILLAC risk score into low risk, intermediate risk and high … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 7 publications
(2 citation statements)
references
References 22 publications
0
2
0
Order By: Relevance
“…10 Given the limitations of the Zwolle score, the CADILLAC score was developed in the same patient population as the Zwolle score, but with the integration of ejection fraction, TIMI flow at the end of PCI, and number of diseased vessels, derived from the database of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial, 27 and validated in the database of the Stent-Primary Angioplasty in Myocardial Infarction trial, 28 but with the aim of predicting mortality at 30 days and 1 year, and not of triaging patients according to their risk during hospitalization. 8,11 As we have seen, the Zwolle score remains the only score that can be used to triage patients according to their risk of developing a complication during their stay in the CICU.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…10 Given the limitations of the Zwolle score, the CADILLAC score was developed in the same patient population as the Zwolle score, but with the integration of ejection fraction, TIMI flow at the end of PCI, and number of diseased vessels, derived from the database of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial, 27 and validated in the database of the Stent-Primary Angioplasty in Myocardial Infarction trial, 28 but with the aim of predicting mortality at 30 days and 1 year, and not of triaging patients according to their risk during hospitalization. 8,11 As we have seen, the Zwolle score remains the only score that can be used to triage patients according to their risk of developing a complication during their stay in the CICU.…”
Section: Discussionmentioning
confidence: 99%
“…Several scores have been studied to predict the prognosis of patients with ACS, principally the Global Registry of Acute Coronary Events (GRACE) score, 5 the thrombolysis end flow in myocardial infarction (TIMI) score, 6 the Zwolle score, 7 and the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) score. 8 These scores include biological markers, which may be falsely elevated in other conditions, and angiographic elements, which cannot be known prior to coronary angiography and percutaneous coronary intervention (PCI). For these reasons, these scores, although having a good predictive value, cannot be used as admission triage scores to predict the prognosis of patients admitted with ACS who have undergone PCI.…”
Section: Methodsmentioning
confidence: 99%